Benzinga

Benzinga

Benzinga

mercredi, septembre 02

Amylyx Pharmaceuticals Inc

AMLXNASDAQ
Trade with Public
Trade with Public
$34.49
0.682.01%
À la clôture: Sep 2, 5:00 PM EST
$34.49
0.682.01%
Après les heures: 4:00 PM EST
AperçuActualitésPrévisions de résultatsÉvénementsObjectifs de coursDonnées financièresSentimentActionnariatComparerOptionsRapport sur les stocks

Amylyx Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Amylyx Pharmaceuticals (AMLX).

Price Target Range — 12 Quarters

Analyst Consensus — 11 Analysts

10Buy
1Hold
Consensus RatingBuy# Analysts11Avg. Consensus PT$28Upside to Avg. PT-19.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 27, 2026GuggenheimSeamus FernandezPT RaiseBuy$55→$57
Aug 19, 2026MizuhoGraig SuvannavejhPT RaiseOutperform$30→$42
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $57

Guggenheim analyst Seamus Fernandez maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $55 to $57.
Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $42

Mizuho analyst Graig Suvannavejh maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from $30 to $42.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $55

Guggenheim analyst Seamus Fernandez maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $40 to $55.
Benzinga Newsdesk

PRO
Baird Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $52

Baird analyst Joel Beatty maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from $28 to $52.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $55

HC Wainwright & Co. analyst Andrew S. Fein maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $34 to $55.
Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $30

Mizuho analyst Graig Suvannavejh maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from $24 to $30.
Benzinga Newsdesk

Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise

Données de marché fournies par API Benzinga

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

© 2026 Benzinga | All Rights Reserved